Randomized Controlled Trial of Infliximab (Remicade) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Infliximab (Primary) ; Antithymocyte globulin; Diphenhydramine; Loratadine; Methylprednisolone; Mycophenolate mofetil; Paracetamol; Prednisone; Tacrolimus
- Indications Inflammation
- Focus Therapeutic Use
- Acronyms CTOT-19
- 12 Feb 2016 Planned End Date changed from 1 Aug 2020 to 1 Sep 2020, according to ClinicalTrials.gov record.
- 12 Feb 2016 Planned primary completion date changed from 1 Aug 2020 to 1 Sep 2020, according to ClinicalTrials.gov record.
- 07 Dec 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.